GO
Loading...

Medicine

More

  • AstraZeneca steps up push into cancer immunotherapy Thursday, 31 Jul 2014 | 8:51 AM ET

    LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.

  • FREETOWN/ ACCRA, July 31- Sierra Leone declared a state of emergency and called in troops to quarantine epicenters of Ebola on Thursday, joining Liberia in imposing tough controls to curb the worst ever outbreak of the virus amid fears it could spread beyond West Africa.

  • July 30- Johnson& Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids. The FDA had advised doctors not to use the devices pending further review.

  • Fight against the Ebola virus is thin on the ground Wednesday, 30 Jul 2014 | 10:33 AM ET
    Medical staff working with Medecins sans Frontieres (MSF) prepare to bring food to patients at the MSF Ebola treatment centre in Kailahun, Sierra Leone, July 20, 2014.

    Countries hit by the deadly virus have few resources to deal with treatment, and outside help is limited. NBC News reports.

  • *Sanofi to file drug for US and EU approval by year-end. PARIS, July 30- A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

  • July 29- Amgen Inc on Tuesday posted higher-than-expected second-quarter profit in a rebound from a disappointing first quarter, helped by strong sales of its rheumatoid arthritis drug Enbrel, and it significantly raised its full-year earnings forecast.

  • July 29- Impax Laboratories Inc said the U.S. Food and Drug Administration issued certain observations regarding violations in the company's manufacturing plant in Taiwan. Shares of Impax, which makes generics and specialty drugs to treat central nervous system disorders, fell about 17 percent to $23.15 premarket on Tuesday.

  • Top doctor dies from Ebola after treating dozens Tuesday, 29 Jul 2014 | 9:18 AM ET

    Two American health workers are currently hospitalized with Ebola in neighboring Liberia. The Ebola outbreak is the largest in history with deaths blamed on the disease not only in Sierra Leone and Liberia, but also Guinea and Nigeria.

  • UPDATE 1-Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 7:51 AM ET

    July 29- Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.

  • Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 7:28 AM ET

    July 29- Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • $1,000 Sovaldi now hepatitis treatment of choice Tuesday, 29 Jul 2014 | 1:57 AM ET

    WASHINGTON— A $1,000- per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.

  • Americans fighting Ebola contract deadly virus Monday, 28 Jul 2014 | 8:10 AM ET
    Staff of the Christian charity Samaritan's Purse putting on protective gear in the ELWA hospital in the Liberian capital Monrovia, July 24, 2014.

    Americans Dr. Kent Brantly and aid worker Nancy Writebol contracted Ebola while working to fight the disease in Liberia. NBC News reports.

  • Virus drugmaker fights pediatricians' new advice Monday, 28 Jul 2014 | 12:01 AM ET

    CHICAGO— A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.

  • The push back on Sovaldi     Friday, 25 Jul 2014 | 2:52 PM ET

    Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.

  • *Whereabouts of dozens of victims in Sierra Leone unknown. FREETOWN, July 25- Sierra Leone officials appealed for help on Friday to trace the first known resident in the capital with Ebola whose family forcibly removed her from a Freetown hospital after testing positive for the deadly disease.

  • July 25- AbbVie Inc, which last week announced plans to buy Dublin- based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly results on surging sales of its Humira treatment for rheumatoid arthritis. Excluding special items, AbbVie earned 82 cents per share.

  • *Novo expects to launch in first EU markets in H1 2015. *Shares in Novo rise 1.6 percent. Prospects for degludec- already on sale separately in Europe under the brand name Tresiba- and the new combination with Victoza are critical for Novo, which is the world's biggest insulin maker.

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • LONDON, July 25- A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

  • July 24- A pivotal trial of Keryx Biopharmaceuticals Inc's experimental drug Zerenex showed that it improved levels of serum phosphorus and iron in patients on kidney dialysis, according to results published on Thursday. The trial involved 441 patients, according to the Journal of the American Society of Nephrology, which published the results.